Mycofoli 700 Tablet contains Mycophenolate Sodium 700 mg, a high-potency immunosuppressant widely used in organ transplant medicine to prevent graft rejection.
This tablet works by inhibiting inosine monophosphate dehydrogenase (IMPDH), suppressing T- and B-lymphocyte proliferation and reducing immune-mediated damage to transplanted organs. It is ideal for patients requiring higher-dose immunosuppression in renal, cardiac, or hepatic transplant regimens, under strict medical supervision.
Clinically, Mycofoli 700 Tablet is used in combination with calcineurin inhibitors and corticosteroids to maintain graft survival, minimize rejection episodes, and ensure post-transplant stability.
The tablet ensures accurate dosing, consistent bioavailability, and reliable therapeutic outcomes, making it suitable for hospitals, transplant centers, specialty pharmacies, and healthcare providers managing intensive post-transplant immunosuppressive therapy.
Common side effects may include nausea, diarrhea, vomiting, abdominal discomfort, headache, and mild infections. Rare but serious effects include leukopenia, anemia, thrombocytopenia, severe infections, and allergic reactions.
Mycofoli 700 Tablet is indicated for the prevention of organ transplant rejection in renal, cardiac, or hepatic transplant recipients. It is also used in the management of certain autoimmune disorders under specialist supervision.
Use Mycofoli 700 Tablet strictly under medical supervision. Regular monitoring of blood counts, liver and kidney function, and infection status is essential. Inform your doctor about any history of bone marrow suppression, infections, or concurrent medications. Avoid live vaccines and seek immediate medical attention if severe infections, unusual bleeding, or persistent fever occur.
Store in a cool, dry place below 25°C. Protect from light and moisture. Keep out of reach of children. Do not use beyond the expiry date.